Trials / Completed
CompletedNCT05055934
Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploratory Study to Evaluate the Effectiveness and Safety of SHR-1314 Injection in Adult Subjects With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical study, consisting of a 4-week screening period, a 12-week core treatment period, a 12-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 111 adult subjects with psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1314 injection | SHR-1314 injection |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2021-10-22
- Primary completion
- 2024-06-05
- Completion
- 2024-06-05
- First posted
- 2021-09-24
- Last updated
- 2024-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05055934. Inclusion in this directory is not an endorsement.